The high cost of prescription drugs in the U.S. is driven by Big Pharma’s patent practices and strategic blocking of affordable generic medications, especially from India. This article reveals how evergreening tactics, intense lobbying, and restrictive FDA regulations keep drug prices artificially high and prevent the entry of cheaper alternatives. These monopoly practices significantly impact consumers, leading to high healthcare costs and limited access to essential medications. Organizations like Ashvin Medicara play a crucial role in advocating for the importation of safe and affordable generics, challenging the power of Big Pharma and supporting policy changes for better healthcare access.